SCHEMBL22160349

SCHEMBL22160349

O=C(CCc1c(-c2ccc(F)cc2)[nH]c2c(C(F)(F)F)cccc12)N[C@@H]1C(=O)NC[C@H]1O

nearest known ligand 0.87

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ APOL1 O14791 20/20 0.87

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22160199 0.93 APOL1 (1.00) APOL1
SCHEMBL22159680 0.90 APOL1 (0.81) APOL1
SCHEMBL24099376 0.88 APOL1 (0.76) APOL1
SCHEMBL22160169 0.88 APOL1 (0.76) APOL1
SCHEMBL22160171 0.88 APOL1 (0.76) APOL1
SCHEMBL22161123 0.86 APOL1 (0.81) APOL1
SCHEMBL31006387 0.86 APOL1 (0.81) APOL1
SCHEMBL22161217 0.85 APOL1 (0.82) APOL1
SCHEMBL31006389 0.85 APOL1 (0.82) APOL1
SCHEMBL22160167 0.85 APOL1 (1.00) APOL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250042878-A1 INHIBITORS OF APOL1 AND METHODS OF USING SAME VERTEX PHARMA (US) 2025-02-06 — — US disclosed
US-12060346-B2 Inhibitors of APOL1 and methods of using same VERTEX PHARMACEUTICALS INCORPORATED (US) 2024-08-13 — — US disclosed
CN-113453760-B APOL1 inhibitors and methods of use thereof 弗特克斯药品有限公司 2024-05-24 — — CN disclosed
US-20230271945-A1 INHIBITORS OF APOL1 AND METHODS OF USING SAME VERTEX PHARMACEUTICALS INCORPORATED 2023-08-31 — — US disclosed
US-20230271945-A1 INHIBITORS OF APOL1 AND METHODS OF USING SAME VERTEX PHARMACEUTICALS INCORPORATED 2023-08-31 — — US disclosed
US-20230271945-A1 INHIBITORS OF APOL1 AND METHODS OF USING SAME VERTEX PHARMACEUTICALS INCORPORATED 2023-08-31 — — US disclosed
US-11618746-B2 Inhibitors of APOL1 and methods of using same VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-04-04 — — US disclosed
US-11618746-B2 Inhibitors of APOL1 and methods of using same VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-04-04 — — US disclosed
CN-113453760-A APOL1 inhibitors and methods of use thereof 弗特克斯药品有限公司 2021-09-28 — — CN disclosed
US-20200377479-A1 INHIBITORS OF APOL1 AND METHODS OF USING SAME Vertex Pharmacéuticals Incorporated 2020-12-03 — — US disclosed
US-20200377479-A1 INHIBITORS OF APOL1 AND METHODS OF USING SAME Vertex Pharmacéuticals Incorporated 2020-12-03 — — US disclosed
WO-2020131807-A1 INHIBITORS OF APOL1 AND METHODS OF USING SAME VERTEX PHARMACEUTICALS INCORPORATED (US) 2020-06-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271945-A1 INHIBITORS OF APOL1 AND METHODS OF USING SAME APOL1, APOB, SAAL1 APOL1 1/4885
US-12060346-B2 Inhibitors of APOL1 and methods of using same APOL1, APOB, SAAL1 APOL1 1/4885
US-20250042878-A1 INHIBITORS OF APOL1 AND METHODS OF USING SAME APOL1, APOB, SAAL1 APOL1 1/4885
US-11618746-B2 Inhibitors of APOL1 and methods of using same APOL1, APOB, NPC1L1 APOL1 1/4885
US-20200377479-A1 INHIBITORS OF APOL1 AND METHODS OF USING SAME APOL1, SAAL1, LOXL1 APOL1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback